Paul Shaughnessy
A5014618029- Hematopoietic Stem Cell Transplantation
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Multiple Myeloma Research and Treatments
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Renal Transplantation Outcomes and Treatments
- Biomedical Ethics and Regulation
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Chronic Myeloid Leukemia Treatments
- Polyomavirus and related diseases
- Childhood Cancer Survivors' Quality of Life
- T-cell and B-cell Immunology
- Biosimilars and Bioanalytical Methods
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Mesenchymal stem cell research
- HIV/AIDS drug development and treatment
- Lymphoma Diagnosis and Treatment
- Transplantation: Methods and Outcomes
- Bacterial Identification and Susceptibility Testing
- Mycobacterium research and diagnosis
- Viral-associated cancers and disorders
Houston Methodist
2020-2025
Methodist Hospital
2020-2025
Sarah Cannon
2015-2025
Methodist Hospital
2021-2025
Methodist Healthcare
2006-2025
University College London
2024
University Hospitals Birmingham NHS Foundation Trust
2024
University Hospitals Bristol NHS Foundation Trust
2024
Cambridge University Hospitals NHS Foundation Trust
2024
University College London Hospitals NHS Foundation Trust
2024
The Ancillary Therapy and Supportive Care Working Group had 3 goals: (1) to establish guidelines for ancillary therapy supportive care in chronic graft-versus-host disease (GVHD), including treatment symptoms recommendations patient education, preventive measures, appropriate follow-up; (2) provide the prevention management of infections other common complications GVHD; (3) highlight areas with greatest need clinical research. definition “ancillary care” embraces most frequent...
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free Patients and Methods Two hundred fifty-four patients 18 65 years age acute leukemia or myelodysplastic...
Peripheral blood progenitor cell mobilization practices vary significantly among institutions. Effective regimens include growth factor alone, chemotherapy and combined, and, more recently, incorporation of plerixafor with either approach. Many institutions have developed algorithms to improve stem success rates cost-effectiveness. However, an optimal regimen has not been defined. Practical guidelines are needed address important clinical questions, including which is optimal, what dose most...
Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses intermediate-affinity CAR to reduce toxic effects and improve persistence. We conducted a phase 1b-2 multicenter study of obe-cel in adults (≥18 years age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A, included patients morphologic disease; 2B had measurable residual disease. primary end point was overall remission...
Related human leukocyte antigen (HLA)-haploidentical bone marrow transplantation (BMT) with posttransplant cyclophosphamide may be curative for sickle cell disease. However, graft failure, severe graft-versus-host disease (GVHD), infections, and mortality remain a concern. We evaluated novel conditioning regimen followed by related HLA-haploidentical BMT in adults In phase 2, open-label, single-arm, multicenter study, 54 eligible participants from 19 U.S. centers were enrolled. Of these, 42...
Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy maribavir with fewer treatment-limiting toxicities than valganciclovir.
Plerixafor plus granulocyte-colony stimulating factor (G-CSF) has been shown to mobilize more CD34(+) cells than G-CSF alone for autologous hematopoietic stem cell transplantation (HSCT). However, many centers use chemotherapy followed by prior HSCT. We performed a retrospective study of patients who participated in the expanded access program (EAP) plerixafor and initial mobilization cells, compared outcomes matched historic controls mobilized with cyclophosphamide 3-5 g/m(2) at 2 that EAP...
6504 Background: Obe-cel is an autologous CAR-T cell product with a fast off-rate CD19 binder designed to mitigate immunotoxicity and improve expansion/persistence. Pooled results from the pivotal FELIX phase Ib/II study (NCT04404660) of obe-cel in adults R/R B-ALL were recently presented (Roddie C et al. Blood 2023;142[Suppl 1]:222). Here, OS EFS all patients (pts) treated are reported, alongside impact persistency consolidative SCT for pts remission. Methods: Pts aged ≥18 yrs enrolled....
On the basis of results ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October 2021 for adults with relapsed/refractory (R/R) B-cell ALL (B-ALL). We report outcomes patients treated brexu-cel as standard therapy.
Significant advances in hematopoietic cell transplantation (HCT) have increased the long-term survivorship of its recipients, but because unique complications arising from radiation and chemotherapy, recipients require lifelong follow-up. To evaluate current or follow-up (LTFU) clinics specifically for HCT survivors to potential barriers their establishment, American Society Blood Marrow Transplantation (ASBMT) Practice Guidelines Committee electronically surveyed 200 programs gather...
We set out to assess feasibility and safety of allogeneic hematopoietic cell transplant in 17 persons with HIV a phase II prospective multicenter trial. The primary endpoint was 100-day nonrelapse mortality (NRM). Patients had an 8/8 HLA-matched related or at least 7/8 unrelated donor. Indications for were acute leukemia, myelodysplasia, lymphoma. Conditioning myeloablative reduced intensity. There no NRM 100 days. cumulative incidence grades IV graft-versus-host disease (GVHD) 41%. At 1...
7000 Background: Obe-cel is an autologous CD19CAR with a fast off-rate CD19 binding domain designed to reduce CAR-T immunotoxicity and improve persistence. Its clinical activity has been tested in r/r paediatric adult B-ALL trials (CARPALL, Ghorashian S et al., Nat Med 2019; ALLCAR19, Roddie C JCO 2021) more recently adults B-cell malignancies (NCT02935257). Here, we present data from patients treated obe-cel the pivotal FELIX study (NCT04404660). Methods: open-label, multi-centre, global,...
Acute graft-versus-host disease (aGVHD) is partly mediated through activated T cells, and these cells are known to express the high-affinity receptor for interleukin 2 (IL-2R). Denileukin diftitox composed of human IL-2 diphtheria toxin that cytotoxic lymphocytes expressing IL-2R. We describe results a phase II study denileukin in 22 patients with steroid-resistant aGVHD. Twenty were treated at dose level 1 (4.5 μg/kg daily on days 1–5 then weekly 8, 15, 22, 29), (9.0 delivered same...